Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended March 31, 2022
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	159	$	159	$	—
License Fee – Over time	62		—		62
Total Drug Products	221		159		62
Concentrate Products
Product Sales – Point-in-time	15,427		13,810		1,617
License Fee – Over time	476		476		—
Total Concentrate Products	15,903		14,286		1,617
Net Revenue	$	16,124	$	14,445	$	1,679

In thousands of U.S. dollars ($)	Three Months Ended March 31, 2021
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	225	$	225	$	—
License Fee – Over time	58		—		58
Total Drug Products	283		225		58
Concentrate Products
Product Sales – Point-in-time	14,705		13,201		1,504
License Fee – Over time	485		485		—
Total Concentrate Products	15,190		13,686		1,504
Net Revenue	$	15,473	$	13,911	$	1,562

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	March 31, 2022		December 31, 2021
Receivables, which are included in "Trade and other receivables"	$	7,121	$	5,913
Contract liabilities	$	7,619	$	8,157